Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02668406
Other study ID # Melioidosis
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 2016
Est. completion date September 30, 2018

Study information

Verified date October 2018
Source Institute of Tropical Medicine, Belgium
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Clinical samples [blood and voided urine (only for phase A)] from patient recruited at Sihanouk Hospital Centre of HOPE (SHCH) and HOPE Community Medical Center (CMC) will be processed (decontamination) and shipped to SRI International with the purpose of design and validation (proof of concept) and (case/control series) of in-vitro diagnostics for melioidosis.


Description:

Study will be proposed to all patients at Sihanouk Hospital Centre of HOPE (SHCH) and HOPE Community Medical Center (CMC) presenting with systemic inflammatory response syndrome (SIRS).

Blood samples will be collected upon admission for patients with blood culture request as part of routine patient care and agreement on informed consent. A second sample will be collected in patients with blood culture proven melioidosis or suspicion of melioidosis (only for phase B), at day 5 after initiation of appropriate antibiotic treatment. Depending on the final diagnosis, a subset of patients will be assigned to 3 groups:

1. Patients for whom blood cultures grew Burkholderia pseudomallei

2. Patients for whom blood cultures did not grow a pathogen, but have other body site grown with Burkholderia pseudomallei, or are suspected of melioidosis

3. Patients for whom blood cultures grew with another pathogen

In phase A only, at least 20 ml of voided urine will be collected when a patient is hospitalized and identified as belonging to study group 1, 2 or 3. A second collection of voided urine will be collected for group 1 and 2 patients during routine further hospital stay or a routine follow-up visit.

The clinical samples from these patients will be processed and shipped to SRI International with the purpose of design (=phase A) and validation (=phase B) of in-vitro diagnostics for melioidosis.

A coded database will be completed with basic demographic, clinical and microbiological data and final diagnosis. This coded information will be provided to SRI International.


Recruitment information / eligibility

Status Completed
Enrollment 4203
Est. completion date September 30, 2018
Est. primary completion date September 30, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult (>18 years old)

- Blood culture request by treating physician as part of standard care

- Willing to give informed consent

Exclusion Criteria:

- Refusal to give informed consent

Study Design


Related Conditions & MeSH terms

  • Melioidosis
  • Suspected or Confirmed Bloodstream Infections
  • Systemic Inflammatory Response Syndrome

Intervention

Other:
Venous blood sampling (2 timepoints) (Phase A and B)
8.5ml at Day 1 + 8.5ml at Day 5
Venous blood sampling (1 timepoint) (Phase A and B)
8.5ml at Day 1
Voided urine sampling (first sample) (Phase A)
At least 20ml upon confirmation of being part of one of the 3 study groups
Voided urine sampling (second sample) (Phase A)
At least 20ml during routine hospital stay or routine follow-up visit

Locations

Country Name City State
Cambodia HOPE Community Medical Center Phnom Penh
Cambodia Sihanouk Hospital Center of HOPE (SHCH), Cambodia Phnom Penh

Sponsors (3)

Lead Sponsor Collaborator
Institute of Tropical Medicine, Belgium Sihanouk Hospital Center of HOPE, SRI International

Country where clinical trial is conducted

Cambodia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical reference panel (blood) Establishment of a quality-assured and well-documented clinical reference panel (cases/control) of human blood samples allowing for the design, development and proof-of-concept validation of an in-vitro diagnostic assay for the diagnosis of melioidosis. 15 months
Primary Clinical reference panel (urine) Establishment of a quality-assured and well-documented clinical reference panel (cases/control) of human voided urine samples allowing for the design, development and proof-of-concept validation of an in-vitro diagnostic assay for the diagnosis of melioidosis. 15 months
See also
  Status Clinical Trial Phase
Completed NCT02518087 - Increased Adsorption Membranes During Cardiopulmonary Bypass N/A
Completed NCT02902939 - Myeloid-Derived Supressor Cells in Cardiac Surgery Patients N/A
Completed NCT02563652 - Can Biomarkers Aid in the Prediction of Postoperative Pain and Circulatory Instability After Major Abdominal Surgery?
Recruiting NCT01157299 - Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO N/A
Completed NCT01388725 - Comparison the Value of Several Biomarkers of Sepsis N/A
Unknown status NCT00254176 - Cysteine Supplementation in Critically Ill Neonates Phase 2/Phase 3
Not yet recruiting NCT03617796 - Prognostic Value of CD64 Marker for Patients in Intensive Care Unit
Completed NCT03876041 - Evaluation of Corticosteroid in Systemic Inflammatory Response Syndrome Phase 4
Recruiting NCT05608096 - European Registry for Hemadsorption in Sepsis With the Seraph Filter
Completed NCT03314831 - The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis
Completed NCT02568410 - Platelets as Regulators of Inflammation in Cardiac Surgery
Completed NCT01636232 - Vitamin D and Critically Ill Patients N/A
Completed NCT01020409 - INFLACOR - Clinical and Genetic Predictors of Inflammation Related Complications After Heart Surgery Phase 4
Completed NCT04624776 - Steroid Treatment After Resuscitated Out-of-Hospital Cardiac Arrest Phase 2
Recruiting NCT05172739 - Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in Elective VATS-Lobectomy for NSCLC Phase 4
Recruiting NCT02957175 - Immunophenotyping of Patients With Postoperative SIRS
Completed NCT02320539 - MicroRNA Diagnostics in Subarachnoid Hemorrhage 2 N/A
Completed NCT01708759 - IL8 Monitoring and Its Correlation With 251-gene Polymorphism N/A
Terminated NCT00708799 - Efficacy of Macrolide Immunomodulation in Severe Sepsis. Phase 2
Recruiting NCT04580680 - Extracorporeal Blood Purification Therapy in Critically Ill Patients (GlobalARRT)